Stay updated on Pembrolizumab in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab in Metastatic NSCLC Clinical Trial page
- Check4 days agoChange DetectedRevision: v3.7.0 was added to the page. A large portion of the Study Documents and related metadata, including document names, contributors, and source information, was removed from the listing.SummaryDifference18%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe study details page history shows a new revision entry v3.6.6 added and the prior revision v3.6.5 removed. This indicates a minor update to the page metadata rather than substantive content changes.SummaryDifference0.1%

- Check46 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a new version of the page documentation. This update changes only the version tag and does not modify the study details shown on the page.SummaryDifference0.1%

- Check61 days agoChange DetectedThe Study Protocol and Statistical Analysis Plan document revision was updated from v3.6.3 to v3.6.4, indicating a newer version is now available.SummaryDifference0.1%

- Check83 days agoChange DetectedThe page’s revision label was updated from v3.6.2 to v3.6.3, indicating a small update to the document or template rather than a change to trial information.SummaryDifference0.1%

- Check90 days agoChange DetectedThe page's revision tag was updated to v3.6.2, replacing the previous v3.6.0 and indicating a refreshed page version.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Metastatic NSCLC Clinical Trial page.